1
|
Gargallo P, Oltra S, Balaguer J, Barranco H, Yáñez Y, Segura V, Juan-Ribelles A, Calabria I, Llavador M, Castel V, Cañete A. Retinoblastoma and mosaic 13q deletion: a case report. Int J Retina Vitreous 2021; 7:50. [PMID: 34479642 PMCID: PMC8418035 DOI: 10.1186/s40942-021-00321-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 08/26/2021] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Patients with 13q-syndrome are at risk of retinoblastoma when the RB1 gene, located in the chromosomal band 13q14.2, is deleted. This syndrome is frequently associated with congenital malformations and developmental delay, although these signs could be mild. Mosaic 13q-deletion patients have been previously reported in the literature; their phenotype is variable, and they may not be recognized. CASE PRESENTATION Retinoblastoma diagnosed in a child with 13q-mosaicism confirmed in blood, oral mucosa, healthy retina and retinoblastoma. A second RB1 hit is present exclusively in the retinoblastoma sample (RB1 c.958C>T p.Arg320Ter). Other detected molecular events in retinoblastoma are 6p12.3pter gain and 6q25.3qter loss. Clinical examination is unremarkable except for clinodactyly of the right fifth finger. DISCUSSION AND CONCLUSIONS We describe a case of mosaic 13q deletion syndrome affected by retinoblastoma. Molecular data obtained from the tumor analysis are similar to previous data available about this malignancy. High clinical suspicion is essential for an adequate diagnosis of mosaic cases.
Collapse
Affiliation(s)
- Pablo Gargallo
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain. .,Oncology Department, Imegen-Health in Code Group, Valencia, Spain.
| | - Silvestre Oltra
- Genetics Unit, La Fe Hospital, Valencia, Spain.,Genetics Department, Valencia University, Valencia, Spain
| | - Julia Balaguer
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.,Oncology Department, Imegen-Health in Code Group, Valencia, Spain.,Genetics Unit, La Fe Hospital, Valencia, Spain.,Genetics Department, Valencia University, Valencia, Spain.,Pediatric Oncology and Hematology Unit, University Hospital La Fe, Valencia, Spain
| | - Honorio Barranco
- Pediatric Ophthalmology Unit, University Hospital La Fe Hospital, Valencia, Spain
| | - Yania Yáñez
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain
| | - Vanessa Segura
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain
| | - Antonio Juan-Ribelles
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.,Oncology Department, Imegen-Health in Code Group, Valencia, Spain.,Genetics Unit, La Fe Hospital, Valencia, Spain.,Genetics Department, Valencia University, Valencia, Spain.,Pediatric Oncology and Hematology Unit, University Hospital La Fe, Valencia, Spain
| | - Inés Calabria
- Oncology Department, Imegen-Health in Code Group, Valencia, Spain
| | | | - Victoria Castel
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain
| | - Adela Cañete
- Clinical and Translational Research in Cancer, Health Research Institute La Fe (IIS La Fe), Valencia, Spain.,Oncology Department, Imegen-Health in Code Group, Valencia, Spain.,Genetics Unit, La Fe Hospital, Valencia, Spain.,Genetics Department, Valencia University, Valencia, Spain.,Pediatric Oncology and Hematology Unit, University Hospital La Fe, Valencia, Spain
| |
Collapse
|